{"id":476317,"date":"2021-04-14T09:33:14","date_gmt":"2021-04-14T13:33:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/"},"modified":"2021-04-14T09:33:14","modified_gmt":"2021-04-14T13:33:14","slug":"shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/","title":{"rendered":"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN FRANCISCO<\/span>, April 14, 2021<\/span> \/PRNewswire\/ —\u00a0Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) relating to possible false statements to investors and insider trading by officers and directors.\u00a0 <\/p>\n

On April 6, 2021<\/span>, FibroGen announced a clarification of certain prior disclosures related to roxadustat, a new drug for the treatment of anemia of chronic kidney disease. Specifically, the company disclosed that the drug’s Phase 3 safety analyses, which were first published in November 2019<\/span>, included “post-hoc changes to the stratification factors” which gave investors a misleading impression of roxadustat’s cardiovascular safety profile. FibroGen further announced that based on analyses using “pre-specified” stratification factors, the company could no longer support certain key conclusions about the drug. FibroGen’s April 6<\/span> disclosure caused a sharp drop in the company’s stock price, wiping out more than $1.3 billion<\/span> of shareholder value.<\/p>\n

Between November 2019<\/span> and April 2021<\/span>, several FibroGen officers and directors sold nearly $11.5 million<\/span> of company stock while outside investors remained unaware of the differing stratification factors.<\/p>\n

The Schubert Firm is investigating potential breaches of fiduciary duty by the company’s directors and officers in connection with these allegations.<\/p>\n

\n If you own stock in FibroGen and wish to obtain additional information about your legal rights, please <\/b>
\n
\n
\n contact us<\/a>
\n <\/u>
\n <\/b>
\n \u00a0today or visit our website at <\/b>
\n
\n
\n https:\/\/www.classactionlawyers.com\/blog\/fibrogen<\/a>
\n <\/u>
\n <\/b>
\n .<\/b>\n <\/p>\n

\n About Schubert Jonckheer & Kolbe
<\/b>
\n
\n Schubert Jonckheer & Kolbe<\/a>
\n <\/u>\u00a0represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco<\/span>, and with the help of co-counsel, litigates cases nationwide.<\/p>\n

\n Contact
<\/b>
\n Alexandra K. Green<\/span>
\n
Schubert Jonckheer & Kolbe
agreen@sjk.law<\/a>
Tel: 415-788-4220<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading-301268684.html<\/a><\/p>\n

SOURCE Schubert Jonckheer & Kolbe LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN FRANCISCO, April 14, 2021 \/PRNewswire\/ —\u00a0Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) relating to possible false statements to investors and insider trading by officers and directors.\u00a0 On April 6, 2021, FibroGen announced a clarification of certain prior disclosures related to roxadustat, a new drug for the treatment of anemia of chronic kidney disease. Specifically, the company disclosed that the drug’s Phase 3 safety analyses, which were first published in November 2019, included “post-hoc changes to the stratification factors” which gave investors a misleading impression of roxadustat’s cardiovascular safety profile. FibroGen further announced that based on analyses using “pre-specified” stratification factors, the company could no longer … <\/p>\n

Continue reading “SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476317","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO, April 14, 2021 \/PRNewswire\/ —\u00a0Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) relating to possible false statements to investors and insider trading by officers and directors.\u00a0 On April 6, 2021, FibroGen announced a clarification of certain prior disclosures related to roxadustat, a new drug for the treatment of anemia of chronic kidney disease. Specifically, the company disclosed that the drug’s Phase 3 safety analyses, which were first published in November 2019, included “post-hoc changes to the stratification factors” which gave investors a misleading impression of roxadustat’s cardiovascular safety profile. FibroGen further announced that based on analyses using “pre-specified” stratification factors, the company could no longer … Continue reading "SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-14T13:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC42078&sd=2021-04-14\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading\",\"datePublished\":\"2021-04-14T13:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/\"},\"wordCount\":313,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC42078&sd=2021-04-14\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/\",\"name\":\"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC42078&sd=2021-04-14\",\"datePublished\":\"2021-04-14T13:33:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC42078&sd=2021-04-14\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC42078&sd=2021-04-14\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO, April 14, 2021 \/PRNewswire\/ —\u00a0Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) relating to possible false statements to investors and insider trading by officers and directors.\u00a0 On April 6, 2021, FibroGen announced a clarification of certain prior disclosures related to roxadustat, a new drug for the treatment of anemia of chronic kidney disease. Specifically, the company disclosed that the drug’s Phase 3 safety analyses, which were first published in November 2019, included “post-hoc changes to the stratification factors” which gave investors a misleading impression of roxadustat’s cardiovascular safety profile. FibroGen further announced that based on analyses using “pre-specified” stratification factors, the company could no longer … Continue reading \"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-14T13:33:14+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC42078&sd=2021-04-14","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading","datePublished":"2021-04-14T13:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/"},"wordCount":313,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC42078&sd=2021-04-14","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/","name":"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC42078&sd=2021-04-14","datePublished":"2021-04-14T13:33:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC42078&sd=2021-04-14","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC42078&sd=2021-04-14"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-fibrogen-inc-fgen-officers-and-directors-under-investigation-for-false-statements-and-insider-trading\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476317"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476317\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}